Dr. Michael Boyle is the Senior Vice-President of Therapeutics Development at the Cystic Fibrosis Foundation and an Adjunct Professor of Medicine at the Johns Hopkins Hospital. Dr. Boyle oversees the clinical development programs of new therapeutics for the CF Foundation, as well as the Foundation’s Therapeutic Development Network (TDN) of 89 academic research centers. Dr. Boyle is internationally known for his clinical research in both CFTR modulators and difficult to treat lung infections, and for his work to improve care for adults with CF. He has been involved in CF care and research for 20 years, including founding and directing the Johns Hopkins Adult CF Program, one of the largest in the United States. He has been the principal investigator for international clinical trials of CFTR modulator therapies including the Orkambi Phase 2 and 3 trials, and been chairman in the past of the TDN steering committee, CFF Adult Care Benchmarking Project, and CFF Patient and Family Education Committee. Dr. Boyle completed all of his medical training at Johns Hopkins including fellowship in pulmonary and critical care medicine before joining their medical faculty in 1999. While there he received numerous honors including the American Lung Association’s George Comstock Career Achievement Award, American Federation of Clinical Research Achievement Award, “Patient’s Choice Award”, “Best Teacher”, and “Best Doctors in America”.